BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
OSPOMYV (denosumab) by Samsung Bioepis is rank ligand blocking activity [moa]. Approved for osteoporosis, postmenopausal osteoporosis, osteopenia and 1 more indications. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OSPOMYV (denosumab) is a monoclonal antibody that blocks RANK ligand to inhibit osteoclast-mediated bone resorption. It is approved for treatment of osteoporosis, postmenopausal osteoporosis, osteopenia, and low bone mineral density. This is a biosimilar entry to the established denosumab market, administered via subcutaneous injection.
Growth
Early-stage biosimilar with growth potential in a competitive $673M market dominated by Amgen's reference product; teams will focus on market penetration and payer education.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications (4)
Worked on OSPOMYV at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.